Nuo Therapeutics has the GF Score of 33, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Nuo Therapeutics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Nuo Therapeutics (OTCPK:AURX) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Nuo Therapeutics GF Score Related Terms
AURX vs PDSB, LTRN, VERU: GF Score Comparison
For the Biotechnology subindustry, Nuo Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuo Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Nuo Therapeutics's GF Score falls into.
Nuo Therapeutics (AURX) has a GF Score of 33 as of Jul. 07, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nuo Therapeutics and its competitors. This is near median its historical median of 33.00. Over the past decade, Nuo Therapeutics' GF Score has ranged from 12.00 to 53.00.
Is Nuo Therapeutics' GF Score too high?
Nuo Therapeutics' current GF Score of 33 is near median its 10-year median of 33.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 53.00. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' GF Score compare to PDSB and LTRN?
Nuo Therapeutics' GF Score of 33 can be compared against companies in the Biotechnology industry. Historically, Nuo Therapeutics' own GF Score has ranged from 12.00 to 53.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Nuo Therapeutics and its competitors. Nuo Therapeutics's current GF Score is 33, which is near median its own 10-year median of 33.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $0.92 — trading 78.5% below its estimated fair value. The current GF Score is 33, which is near median its 10-year median of 33.00. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current GF Score is 33 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nuo Therapeutics (AURX) Overvalued in 2026?
Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued.
The current stock price of $0.92 is trading 78.5% below its estimated GF Value™ of $4.27.
GuruFocus considers Nuo Therapeutics to be Possible Value Trap.
Key valuation signals for AURX:
GF Score: 33 (near median its 10-year median of 33.00)
GF Value™: $4.27 vs. price of $0.92 (78.5% below fair value)
No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score
Get the complete analysis for AURX
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AURX has been successfully added to your 